Literature DB >> 28025082

Identification of G-quadruplex DNA/RNA binders: Structure-based virtual screening and biophysical characterization.

Roberta Rocca1, Federica Moraca1, Giosuè Costa2, Matteo Nadai3, Matteo Scalabrin3, Carmine Talarico1, Simona Distinto4, Elias Maccioni4, Francesco Ortuso1, Anna Artese1, Stefano Alcaro5, Sara N Richter3.   

Abstract

BACKGROUND: Recent findings demonstrated that, in mammalian cells, telomere DNA (Tel) is transcribed into telomeric repeat-containing RNA (TERRA), which is involved in fundamental biological processes, thus representing a promising anticancer target. For this reason, the discovery of dual (as well as selective) Tel/TERRA G-quadruplex (G4) binders could represent an innovative strategy to enhance telomerase inhibition.
METHODS: Initially, docking simulations of known Tel and TERRA active ligands were performed on the 3D coordinates of bimolecular G4 Tel DNA (Tel2) and TERRA (TERRA2). Structure-based pharmacophore models were generated on the best complexes and employed for the virtual screening of ~257,000 natural compounds. The 20 best candidates were submitted to biophysical assays, which included circular dichroism and mass spectrometry at different K+ concentrations.
RESULTS: Three hits were here identified and characterized by biophysical assays. Compound 7 acts as dual Tel2/TERRA2 G4-ligand at physiological KCl concentration, while hits 15 and 17 show preferential thermal stabilization for Tel2 DNA. The different molecular recognition against the two targets was also discussed.
CONCLUSIONS: Our successful results pave the way to further lead optimization to achieve both increased selectivity and stabilizing effect against TERRA and Tel DNA G4s. GENERAL SIGNIFICANCE: The current study combines for the first time molecular modelling and biophysical assays applied to bimolecular DNA and RNA G4s, leading to the identification of innovative ligand chemical scaffolds with a promising anticancer profile. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Circular dichroism; G-quadruplex DNA; Mass spectrometry; TERRA; Virtual screening

Mesh:

Substances:

Year:  2016        PMID: 28025082     DOI: 10.1016/j.bbagen.2016.12.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  14 in total

1.  In Silico Identification of Piperidinyl-amine Derivatives as Novel Dual Binders of Oncogene c-myc/c-Kit G-quadruplexes.

Authors:  Roberta Rocca; Federica Moraca; Giosuè Costa; Carmine Talarico; Francesco Ortuso; Silvia Da Ros; Giulia Nicoletto; Claudia Sissi; Stefano Alcaro; Anna Artese
Journal:  ACS Med Chem Lett       Date:  2018-07-10       Impact factor: 4.345

2.  Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids.

Authors:  Rita Meleddu; Vilma Petrikaite; Simona Distinto; Antonella Arridu; Rossella Angius; Lorenzo Serusi; Laura Škarnulytė; Ugnė Endriulaitytė; Miglė Paškevičiu Tė; Filippo Cottiglia; Marco Gaspari; Domenico Taverna; Serenella Deplano; Benedetta Fois; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-12-18       Impact factor: 4.345

Review 3.  G-quadruplex virtual drug screening: A review.

Authors:  Robert C Monsen; John O Trent
Journal:  Biochimie       Date:  2018-06-30       Impact factor: 4.079

4.  Myoblast Myogenic Differentiation but Not Fusion Process Is Inhibited via MyoD Tetraplex Interaction.

Authors:  Stefano Testa; Pietro D'Addabbo; Ersilia Fornetti; Roberta Belli; Claudia Fuoco; Sergio Bernardini; Stefano Cannata; Domenico Frezza; Cesare Gargioli
Journal:  Oxid Med Cell Longev       Date:  2018-05-07       Impact factor: 6.543

Review 5.  Non-coding RNAs in cancer: platforms and strategies for investigating the genomic "dark matter".

Authors:  Katia Grillone; Caterina Riillo; Francesca Scionti; Roberta Rocca; Giuseppe Tradigo; Pietro Hiram Guzzi; Stefano Alcaro; Maria Teresa Di Martino; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  J Exp Clin Cancer Res       Date:  2020-06-20

Review 6.  The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.

Authors:  Eugenio Morelli; Annamaria Gullà; Roberta Rocca; Cinzia Federico; Lavinia Raimondi; Stefano Malvestiti; Valter Agosti; Marco Rossi; Giosuè Costa; Gianluca Giavaresi; Kareem A Azab; Antonia Cagnetta; Michele Cea; Pierosandro Tagliaferri; Antonino Neri; Nikhil C Munshi; Giuseppe Viglietto; Pierfrancesco Tassone; Nicola Amodio
Journal:  Cancers (Basel)       Date:  2020-01-30       Impact factor: 6.639

7.  Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors.

Authors:  Annalisa Maruca; Delia Lanzillotta; Roberta Rocca; Antonio Lupia; Giosuè Costa; Raffaella Catalano; Federica Moraca; Eugenio Gaudio; Francesco Ortuso; Anna Artese; Francesco Trapasso; Stefano Alcaro
Journal:  Molecules       Date:  2020-05-06       Impact factor: 4.411

8.  TERRA G-quadruplex RNA interaction with TRF2 GAR domain is required for telomere integrity.

Authors:  Yang Mei; Zhong Deng; Olga Vladimirova; Nitish Gulve; F Brad Johnson; William C Drosopoulos; Carl L Schildkraut; Paul M Lieberman
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.996

9.  Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7.

Authors:  Annalisa Maruca; Roberta Rocca; Raffaella Catalano; Francesco Mesiti; Giosuè Costa; Delia Lanzillotta; Alessandro Salatino; Francesco Ortuso; Francesco Trapasso; Stefano Alcaro; Anna Artese
Journal:  Molecules       Date:  2020-11-25       Impact factor: 4.411

10.  Spectroscopic and In Silico Studies on the Interaction of Substituted Pyrazolo[1,2-a]benzo[1,2,3,4]tetrazine-3-one Derivatives with c-Myc G4-DNA.

Authors:  Simone Mulliri; Aatto Laaksonen; Pietro Spanu; Riccardo Farris; Matteo Farci; Francesco Mingoia; Giovanni N Roviello; Francesca Mocci
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.